Showing results (131-140 of 267) with videos related to
Sort By:
Pageof 27
Plos One|November 14, 2013
Circulating CD4+CD161+ T lymphocytes are increased in seropositive arthralgia patients but decreased in patients with newly diagnosed rheumatoid arthritisPaulina Chalan, Bart-Jan Kroesen, Kornelis S M van der Geest, et al.Rheumatology (Oxford, England)|February 12, 2026
Glucocorticoid tapering strategies in polymyalgia rheumatica: a systematic literature reviewNoortje E S E P Kooijman, Bart J F van den Bemt, Lenny van Bon, et al.Rheumatology Advances in Practice|February 11, 2026
Patient experiences of PMR: a qualitative narrative literature reviewMax Yates, Janice Mooney, Pratyasha Saha, et al.RMD Open|January 11, 2023
Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohortIdil Esen, Suzanne Arends, Berit Dalsgaard Nielsen, et al.Rheumatology (Oxford, England)|March 1, 2015
Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumaticaKornelis S M van der Geest, Wayel H Abdulahad, Abraham Rutgers, et al.Rheumatology (Oxford, England)|March 14, 2025
Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritisShuang Xu, William Jiemy, Yannick van Sleen, et al.Frontiers in Nuclear Medicine|March 25, 2025
18F-FDG-PET/CT for polymyalgia rheumatica: agreement and diagnostic accuracy of routine PET scan report vs. standardized PMR PET scoresKornelis S M van der Geest, Rob G J Grootelaar, Karin Bouwman, et al.Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|January 28, 2020
The Patients' Perspective of Important Glucocorticoid Effects: A Nominal Group Study Among Patients With Systemic Lupus Erythematosus and MyositisSerene Z Mirza, Jonathan T L Cheah, Nilasha Ghosh, et al.Arthritis & Rheumatology (Hoboken, N.J.)|July 22, 2025
Late-Onset Spondylarthritis Presenting as Glucocorticoid-Resistant Polymyalgia Rheumatica: A hitherto underappreciated entity where TNF or IL-17 Blockade may have a Therapeutic RoleKerem Abacar, Gabriele De Marco, Jake Weddell, et al.The Lancet. Rheumatology|January 27, 2024
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trialJohn H Stone, Jian Han, Martin Aringer, et al.Pageof 27